BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 34749168)

  • 21. Clinical and biological characteristics of acute myeloid leukemia with 20-29% blasts: a retrospective single-center study.
    Mei C; Ren Y; Zhou X; Ye L; Ma L; Luo Y; Lin P; Xu W; Lu C; Yang H; Yu W; Mao L; Wei J; Jin J; Tong H
    Leuk Lymphoma; 2019 May; 60(5):1136-1145. PubMed ID: 30301399
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characteristics of acute myeloid leukemia with myelodysplasia-related changes: A retrospective analysis in a cohort of Chinese patients.
    Xu XQ; Wang JM; Gao L; Qiu HY; Chen L; Jia L; Hu XX; Yang JM; Ni X; Chen J; Lü SQ; Zhang WP; Song XM
    Am J Hematol; 2014 Sep; 89(9):874-81. PubMed ID: 24861848
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CircZBTB46 predicts poor prognosis and promotes disease progression of myelodysplastic syndromes and acute myeloid leukemia.
    Li S; Zhao G; Wu W; Li N; Wang Q; Wang W; Song X; Wang X
    Clin Exp Med; 2023 Dec; 23(8):4649-4664. PubMed ID: 37930606
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overexpression of Bcl2 protein predicts chemoresistance in acute myeloid leukemia: its correlation with FLT3.
    Mehta SV; Shukla SN; Vora HH
    Neoplasma; 2013; 60(6):666-75. PubMed ID: 23906301
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic alteration patterns and clinical outcomes of elderly and secondary acute myeloid leukemia.
    Wang SY; Cheng WY; Mao YF; Zhu YM; Liu FJ; Ma TT; Shen Y
    Hematol Oncol; 2019 Oct; 37(4):456-463. PubMed ID: 31348835
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
    Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
    Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Utility of 5-Methylcytosine Immunohistochemical Staining to Assess Global DNA Methylation and Its Prognostic Impact in MDS Patients.
    Chandra D; Tyagi S; Singh J; Deka R; Manivannan P; Mishra P; Pati HP; Saxena R
    Asian Pac J Cancer Prev; 2017 Dec; 18(12):3307-3313. PubMed ID: 29286224
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IS THE AMPLIFICATION OF c-MYC, MLL AND RUNX1 GENES IN AML AND MDS PATIENTS WITH TRISOMY 8, 11 AND 21 A FACTOR FOR A CLONAL EVOLUTION IN THEIR KARYOTYPE?
    Angelova S; Spassov B; Nikolova V; Christov I; Tzvetkov N; Simeonova M
    Tsitol Genet; 2015; 49(3):25-32. PubMed ID: 26214902
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms.
    Greco M; D'Alò F; Scardocci A; Criscuolo M; Fabiani E; Guidi F; Di Ruscio A; Migliara G; Pagano L; Fianchi L; Chiusolo P; Hohaus S; Leone G; Voso MT
    Blood Cells Mol Dis; 2010 Oct; 45(3):181-5. PubMed ID: 20655775
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group.
    Eichenauer DA; Thielen I; Haverkamp H; Franklin J; Behringer K; Halbsguth T; Klimm B; Diehl V; Sasse S; Rothe A; Fuchs M; Böll B; von Tresckow B; Borchmann P; Engert A
    Blood; 2014 Mar; 123(11):1658-64. PubMed ID: 24478403
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapy-related myelodysplastic syndrome/acute myeloid leukemia with del(7)(q22) in a patient with de novo AML.
    Kim YG; Cho SY; Park TS; Oh SH; Yoon HJ
    Ann Clin Lab Sci; 2011; 41(1):79-83. PubMed ID: 21325260
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Effects of Human BDH2 on the Cell Cycle, Differentiation, and Apoptosis and Associations with Leukemia Transformation in Myelodysplastic Syndrome.
    Yang WC; Lin SF; Wang SC; Tsai WC; Wu CC; Wu SC
    Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32344823
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Eprenetapopt Plus Azacitidine in
    Cluzeau T; Sebert M; Rahmé R; Cuzzubbo S; Lehmann-Che J; Madelaine I; Peterlin P; Bève B; Attalah H; Chermat F; Miekoutima E; Rauzy OB; Recher C; Stamatoullas A; Willems L; Raffoux E; Berthon C; Quesnel B; Loschi M; Carpentier AF; Sallman DA; Komrokji R; Walter-Petrich A; Chevret S; Ades L; Fenaux P
    J Clin Oncol; 2021 May; 39(14):1575-1583. PubMed ID: 33600210
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia.
    Sekeres MA; Maciejewski JP; Erba HP; Afable M; Englehaupt R; Sobecks R; Advani A; Seel S; Chan J; Kalaycio ME
    Cancer; 2011 Mar; 117(6):1253-61. PubMed ID: 20960521
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytogenetically unrelated clones in therapy-related myelodysplasia and acute myeloid leukemia: experience from the Copenhagen series updated to 180 consecutive cases.
    Pedersen-Bjergaard J; Timshel S; Andersen MK; Andersen AS; Philip P
    Genes Chromosomes Cancer; 1998 Dec; 23(4):337-49. PubMed ID: 9824207
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Allo-HSCT for acute myeloid leukemia with myelodysplastic-related changes: a clinical analysis].
    Zhang HX; Pang AM; Chen X; Zhang RL; Zhai WH; Ma QL; Yang DL; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
    Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):814-822. PubMed ID: 34788920
    [No Abstract]   [Full Text] [Related]  

  • 37. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases.
    Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Fu B; Tang G; Goswami M; Singh R; Kanagal-Shamanna R; Pierce SA; Young KH; Kantarjian HM; Medeiros LJ; Luthra R; Wang SA
    Leuk Res; 2015 Mar; 39(3):348-54. PubMed ID: 25573287
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MYC protein expression is an important prognostic factor in acute myeloid leukemia.
    Ohanian M; Rozovski U; Kanagal-Shamanna R; Abruzzo LV; Loghavi S; Kadia T; Futreal A; Bhalla K; Zuo Z; Huh YO; Post SM; Ruvolo P; Garcia-Manero G; Andreeff M; Kornblau S; Borthakur G; Hu P; Medeiros LJ; Takahashi K; Hornbaker MJ; Zhang J; Nogueras-González GM; Huang X; Verstovsek S; Estrov Z; Pierce S; Ravandi F; Kantarjian HM; Bueso-Ramos CE; Cortes JE
    Leuk Lymphoma; 2019 Jan; 60(1):37-48. PubMed ID: 29741984
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome.
    Cleven AH; Nardi V; Ok CY; Goswami M; Dal Cin P; Zheng Z; Iafrate AJ; Abdul Hamid MA; Wang SA; Hasserjian RP
    Mod Pathol; 2015 Apr; 28(4):552-63. PubMed ID: 25412846
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clonal Hematopoiesis and therapy related MDS/AML.
    Desai P; Roboz GJ
    Best Pract Res Clin Haematol; 2019 Mar; 32(1):13-23. PubMed ID: 30927970
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.